Anemia and lung cancer

Lung Cancer

Volumn 38, Issue 3 SUPPL., 2002, Pages

  Crawford, Jeffrey ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; HALF LIFE TIME; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; LUNG CARCINOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 0036896230     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0169-5002(02)00275-1     Document Type: Review

References (24)

1. Groopman J.E., Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl. Cancer Inst. 91:1999;1616-1633.
2. Nowrousian M.R. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med. Oncol. 15:(1):1998;S19-S28.
3. Dalton J.D., Bailey N.P., Barrett-Lee P.J., et al. Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy. Proc. Am. Soc. Clin. Oncol. 17:1998;418a. (Abstract 1611).
4. Langer C., Barsevick A., Bruner D., et al. Correlation of quality of life (QOL) with survival, treatment response, and anemia in patients with advanced non-small cell lung cancer (NSCLC) treated with carboplatin and paclitaxel. Lung Cancer. 18:1997;23. (Abstract 79).
5. Thatcher N. Management of chemotherapy-induced anemia in solid tumors. Semin. Oncol. 3:(Suppl. 7):1998;23-26.
6. Okamoto H., Saijo N., Shinkai T., et al. Chemotherapy-induced anemia in patients with primary lung cancer. Ann. Oncol. 3:1992;819-824.
7. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J. Clin. Oncol. 15:1997;2996-3018.
8. Henke M., Guttenberger R., Barke A., et al. Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother. Oncol. 50:1999;185-190.
9. Logsdon M.D., Eifel P.J. FIGO IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 43:1999;763-775.
10. Stadler P., Becker A., Feldmann H.J., et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 44:1999;749-754.
11. Albain K.S., Crowley J.J., LeBlanc M., et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J. Clin. Oncol. 9:1991;1618-1626.
12. Manegold C. The causes and prognostic significance of low hemoglobin levels in tumor patients. Strahlenther. Onkol. 174:(Suppl. IV):1998;17-19.
13. Miller C.B., Jones R.J., Piantadosi S., et al. Decreased erythropoietin response in patients with the anemia of cancer. N. Engl. J. Med. 322:1990;1689-1692.
14. Abels R. Erythropoietin for anaemia in cancer patients. Eur. J. Cancer. 29A:(Suppl. 2):1993;S2-S8.
15. Glaspy J., Bukowski R., Steinberg D., et al. Impact of therapy with epoetin alpha on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J. Clin. Oncol. 15:1997;1218-1234.
16. Demetri G.D., Kris M., Wade J., et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alpha is independent of disease response or tumor type: results from a prospective community oncology study. J. Clin. Oncol. 16:1998;3412-3425.
17. Gabrilove J.L., Cleeland C.S., Livingston R.B., et al. Clinical evaluation of once-weekly dosing of epoetin alpha in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J. Clin. Oncol. 19:2001;2875-2882.
18. Littlewood T.J., Bajetta E., Nortier J.W.R., Vercammen E., Rapoport B. Effects of epoetin alpha on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized double-blind placebo-controlled trial. J. Clin. Oncol. 19:(11):2001;2865-2874.
19. Crawford J., Demetri G.D., Gabrilove J.L., Blasi M.V., Sarokhan B.J., Glaspy J. Clinical benefits of epoetin alpha therapy in patients with lung cancer. Clin. Lung Cancer. 3:(3):2002;180-190.
20. Egrie J.C., Browne J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). Blood. 84:(Suppl. 1):2001;3-10.
21. Pirker R., Vansteenkiste J., Gateley J., Yates P., Colowick A., Musil J. A phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum-treatment for lung cancer. Proc. ASCO. 20:(1):2001;394a.
22. Crawford J., Cella D., Cleeland C.S., Cremieux P-Y., Demetri G.D., Sarokhan B.J., Slavin M.B., Glaspy J.A. Relationship between changes in haemoglobin level and quality of life during chemotherapy in anaemic cancer patients receiving epoetin alpha therapy. Cancer. 95:2002;888-895.
23. Finch C.A. Erythropoiesis, erythropoietin, and iron. Blood. 60:1982;1241-1246.
24. Shasha D, George M, Harrison L. Once weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy, Blood 2000;96(suppl 1), abst. 916.